Diagnostic Imaging of Cancers: Role of PET/CT

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 3224

Special Issue Editor


E-Mail Website
Guest Editor
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), D-68120 Heidelberg, Germany
Interests: nuclear medicine; positron emission tomography (PET); fibroblast activation protein inhibitor (FAPi); cancer imaging; diagnostic imaging; microstructural imaging; brain tumors; head & neck cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Positron emission tomography (PET) is becoming more and more relevant for the diagnostic imaging of cancers. The value of already clinically available tracers, such as 18F-FDG, 18F-, and 68Ga-PSMA ligands, or 68Ga-DOTATOC/DOTATAE, is increasingly recognized by clinicians, and PET imaging plays an emerging role for the workup of various cancers. On the other hand, new PET tracer molecules, including fibroblast activation protein inhibitors (FAPI tracers), estrogen receptor- or HER2-targeted imaging for breast cancer, or CXCR4-targeted imaging of hematological malignancies, provide new insights into the molecular characteristics of cancers and offer new approaches for staging and therapy response evaluation. Beyond new tracers, new PET scanners with markedly increased fields of views allow fast dynamic and parametric imaging of the whole body and are expected to radically change the clinical setting of oncological PET imaging.

In this Special Issue of Cancers, entitled “Diagnostic Imaging of Cancers: Role of PET/CT”, we welcome original scientific contributions that focus on innovative clinical and preclinical approaches for the PET imaging of cancers.

Dr. Manuel Röhrich
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PET
  • CT
  • FAP ligand
  • diagnostic imaging
  • radiation therapy
  • nuclear medicine

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

8 pages, 2453 KiB  
Article
Intra-Individual Comparison of Physiologic [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis
by Emil Novruzov, Dominik Schmitt, Katalin Mattes-György, Markus Beu, Yuriko Mori, Mardjan Dabir, Jan Philipp Radtke, Günter Niegisch, Peter Albers, Lars Schimmöller, Gerald Antoch, Christina Antke, Frederik L. Giesel and Eduards Mamlins
Cancers 2023, 15(10), 2787; https://doi.org/10.3390/cancers15102787 - 17 May 2023
Viewed by 1317
Abstract
Background: Several studies indicate, particularly in the case of [18F]PSMA-1007, a relatively high rate of detection of ganglia in PSMA PET imaging. Ganglia are an integral part of the sympathetic portion of the autonomous nervous system. To date, no studies have directly compared [...] Read more.
Background: Several studies indicate, particularly in the case of [18F]PSMA-1007, a relatively high rate of detection of ganglia in PSMA PET imaging. Ganglia are an integral part of the sympathetic portion of the autonomous nervous system. To date, no studies have directly compared [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 ganglionic uptake intra-individually and analyzed the underlying molecular and physical mechanisms of different detection rates. With this monocentric retrospective study, we sought to evaluate the intra-individual physiological ganglion uptake of these different PSMA ligands in evidence-based imaging for prostate cancer. Methods: Our cohort consists of 19 male patients (median age 72 ± 9 with a range of 56–85) with biochemical recurrence of prostate cancer who underwent both [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT in our clinic on the same scanner per standard care between March 2015 and March 2022. Tracer uptake was quantified according to maximum standardized uptake value (SUVmax) for both [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT scans. Ganglia-to-background ratios (GBRs) were determined to quantify the image contrast through dividing the SUVmax of the ganglia by the background value (SUVmax of blood pool in the descending aorta, fatty tissue, and skeletal muscle in gluteal region). We used descriptive analyses for demographics and tumor characteristics and performed two-way repeated-measures ANOVA (analysis of variance) for SUV metrics including GBR measurements. Results: In total, we examined 101 ganglia with [18F]PSMA-1007 scanning, localized mostly in pairs as stellate, coeliac, and sacral, of which 76 were also detected with [68Ga]Ga-PSMA-11 PET/CT scanning. There was no statistically significant difference in PSMA uptake in terms of SUVmax between [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 (p value: 0.052). In contrast, the comparison of GBRs revealed a higher detectability rate of ganglia with [18F]PSMA-1007 imaging (p < 0.001). Furthermore, a separate comparison of ganglia with respect to their anatomical location also demonstrated statistically significant differences both within and between [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET/CT scans. Conclusion: Given the impression of more accentuated [18F]PSMA-1007 uptake in ganglia compared with 68Ga-labelled counterparts, our study demonstrated that the better detectability of ganglia is not due to more intense [18F]PSMA-1007 uptake by these small structures but to much more favorable physical properties of the radionuclide 18F. The most relevant limitations of our study are its retrospective design and the small patient cohort. Full article
(This article belongs to the Special Issue Diagnostic Imaging of Cancers: Role of PET/CT)
Show Figures

Figure 1

Other

Jump to: Research

12 pages, 634 KiB  
Systematic Review
18F-FDG PET/CT Maximum Tumor Dissemination (Dmax) in Lymphoma: A New Prognostic Factor?
by Domenico Albano, Giorgio Treglia, Francesco Dondi, Anna Calabrò, Alessio Rizzo, Salvatore Annunziata, Luca Guerra, Silvia Morbelli, Alessandra Tucci and Francesco Bertagna
Cancers 2023, 15(9), 2494; https://doi.org/10.3390/cancers15092494 - 26 Apr 2023
Cited by 7 | Viewed by 1563
Abstract
Recently, several studies introduced the potential prognostic usefulness of maximum tumor dissemination (Dmax) measured by 2-deoxy-2-fluorine-18-fluoro-D-glucose positron-emission tomography/computed tomography (18F-FDG PET/CT). Dmax is a simple three-dimensional feature that represents the maximal distance between the two farthest hypermetabolic PET lesions. A comprehensive [...] Read more.
Recently, several studies introduced the potential prognostic usefulness of maximum tumor dissemination (Dmax) measured by 2-deoxy-2-fluorine-18-fluoro-D-glucose positron-emission tomography/computed tomography (18F-FDG PET/CT). Dmax is a simple three-dimensional feature that represents the maximal distance between the two farthest hypermetabolic PET lesions. A comprehensive computer literature search of PubMed/MEDLINE, Embase, and Cochrane libraries was conducted, including articles indexed up to 28 February 2023. Ultimately, 19 studies analyzing the value of 18F-FDG PET/CT Dmax in patients with lymphomas were included. Despite their heterogeneity, most studies showed a significant prognostic role of Dmax in predicting progression-free survival (PFS) and overall survival (OS). Some articles showed that the combination of Dmax with other metabolic features, such as MTV and interim PET response, proved to better stratify the risk of relapse or death. However, some methodological open questions need to be clarified before introducing Dmax into clinical practice. Full article
(This article belongs to the Special Issue Diagnostic Imaging of Cancers: Role of PET/CT)
Show Figures

Figure 1

Back to TopTop